title: [Role of matrix metalloproteinases-9, 2 and their inhibitor-TIMP-1, 2 in invasive pituitary adenomas biological behavior].
abstract: OBJECTIVE
  Usually pituitary adenomas are histological benign and grow slowly, but a proportion of them will become locally aggressive, and develop into invasive pituitary adenomas. The reasons for these differences in tumor behavior are poorly understood. Pituitary adenomas are abounding blood vessels. Angiogenesis and tumor invasion both require degradation of the extracellular matrix components to allow cell migration. The matrix metalloproteinases (MMPs) and their nature inhibitors-the tissue inhibitors of metalloproteinases (TIMPs) may play a central role in these processes. The aggressive mechanism of pituitary adenomas was studied through investigating the expression of MMP-9, MMP-2, TIMP-1, and TIMP-2 in both invasive and non-invasive adenomas.
  
  
  METHODS
  Sixty-one surgical removed pituitary adenomas (forty-nine cases invasive and twelve non-invasive adenomas) were investigated. Immunohistochemistry staining (SP method) was used to detect the expression of MMP-9, MMP-2, TIMP-1, and TIMP-2 in two groups. The results were treated with semi-quantitative method and analyzed by using non-parameter rank sum test.
  
  
  RESULTS
  Immunohistochemical staining of tumor cells for MMP-9, TIMP-1, MMP-2, and TIMP-2 were noted 95.9% (47/49), 57.1% (28/49), 75.5% (37/49) and 89.8% (44/49) in invasive adenomas, and 100% (12/12), 91.7% (11/12), 66.7% (8/12), and 91.7% (11/12) in non-invasive adenomas, respectively. Invasive tumors were significantly less expressing TIMP-1 and TIMP-2 (P < 0.05). There was no significant difference for MMP-9 or MMP-2 between invasive and non-invasive groups (P > 0.05).
  
  
  CONCLUSIONS
  TIMP-1 and TIMP-2 may play a key role in invasive pituitary adenomas to biological behavior.
authors.affiliation: Department of Neurosurgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, P. R. China. gzhedongsheng@sohu.com
authors.forename: Dong-sheng
authors.initials: DS
authors.lastname: He
authors.forename: Ming-zhen
authors.initials: MZ
authors.lastname: Chen
authors.forename: Hai-jun
authors.initials: HJ
authors.lastname: Wang
authors.forename: Chun-long
authors.initials: CL
authors.lastname: Ke
authors.forename: Chao
authors.initials: C
authors.lastname: Yan
authors.forename: Heng
authors.initials: H
authors.lastname: Zheng
authors.forename: Yi-shan
authors.initials: YS
authors.lastname: Hong
mesh_terms: D000236:Adenoma / Q000378:metabolism / Q000473:pathology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis; D020782:Matrix Metalloproteinases / Q000096:biosynthesis*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010911:Pituitary Neoplasms / Q000378:metabolism / Q000473:pathology*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000096:biosynthesis; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000096:biosynthesis; D019714:Tissue Inhibitor of Metalloproteinases / Q000096:biosynthesis*
chemical_list: D019715:Tissue Inhibitor of Metalloproteinase-1; D019714:Tissue Inhibitor of Metalloproteinases; D019716:Tissue Inhibitor of Metalloproteinase-2; D020782:Matrix Metalloproteinases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9